



MINISTERIO  
DE ECONOMÍA  
Y COMPETITIVIDAD

isc  
Instituto  
de Salud  
Carlos III

## Taller de oportunidades sobre SALUD MENTAL Y NEUROCIENCIAS en H2020

# SALUD MENTAL y NEUROCIENCIAS en los diferentes pilares de Horizon 2020: HEALTH, FOOD, NMBP y Ciencia excelente

**2 de diciembre de 2015**

**Juan E. Riese PhD MBA**

Punto Nacional de Contacto – Reto Social 1 H2020


Oficina de Proyectos Europeos

*Subdirección General de Programas Internacionales  
de Investigación y Relaciones Institucionales*

- Financiación de la I+D+i en Salud Mental y Neurociencias en H2020
  - Oportunidades en Pilares 1, 2 y 3
- Oportunidades en la Iniciativa de Medicamentos Innovadores (IMI2)
- Oportunidades en ERA-Nets y JPIs

- Financiación de la I+D+i en Salud Mental y Neurociencias en H2020
  - Oportunidades en Pilares 1, 2 y 3
- Oportunidades en la Iniciativa de Medicamentos Innovadores (IMI2)
- Oportunidades en ERA-Nets y JPIs

# Resumen de H2020



# Pilar 1 – Ciencia Excelente

- **ERC-IDEAS: 13.268 M€** (twice in comparison to FP7)
  - More focused on young researchers and basic research, but
  - Don't forget the view on impact!
- **FET (Future and Emergent Technologies): 3.100 M€**
  - ICT as tools in order to reach set goals
  - **Marie Skłodowska Curie (Mobility): 5.752 M€ (=FP7)**
  - Similar to Fp7
- **Infraestructures (ESFRI): 2.478 M€ (x2 in comparison to FP7)**
  - An instrument for setting up the ERA
  - To foster access to European infrastructures

# Pilar 1. Las “convocatorias ERC”

## Starting Grants

starters  
(2-7 years after PhD) up  
to € 2.0 Mio  
for 5 years

Al menos 1 publicación  
importante sin el  
supervisor de tesis

## Consolidator Grants

consolidators  
(7-12 years after PhD)  
up to € 2.75 Mio  
for 5 years

Al menos varias  
publicaciones  
importantes sin el  
supervisor de tesis

## Advanced Grants

track-record of  
significant research  
achievements in the  
last 10 years  
up to € 3.5 Mio  
for 5 years

## Synergy Grants

*2 – 4 Principal Investigators  
up to € 15.0 Mio for 6 years*

## Proof-of-Concept

bridging gap between research - earliest stage  
of marketable innovation  
up to €150,000 for ERC grant holders

<http://ec.europa.eu/programmes/horizon2020/en/h2020-section/european-research-council>

# Pilar 1. Las acciones Marie Skłodowska-Curie (MSCA)

## Individual Fellowships (IF)

Apoyo desarrollo carrera  
mediante movilidad  
internacional - intersectorial

## Innovative Training Networks (ITN)

Redes de formación de jóvenes  
investigadores con participación  
empresarial

## Research and Innovation Staff Exchange (RISE)

Intercambio de personal para  
cooperación intersectorial -  
internacional

## Co-funding of programmes (COFUND)

Co-financiación programas  
internacionales, nacionales,  
regionales

## European Researchers' Night (NIGHT)

Acciones de apoyo a la divulgación  
científica

<http://ec.europa.eu/programmes/horizon2020/en/h2020-section/marie-sklodowska-curie-actions>

## Call - FET Proactive – Boosting emerging technologies

### ■ *H2020-FETPROACT-2016-2017*

Proposals are invited against the following topic(s):

#### **Area 2: Biotech for better life**

- a. Intra- and inter-cell bio-technologies: new technologies to enable the study and engineering of processes within and between biological cells, and their exploitation for purposes such as sensing, signalling, imaging, regulating, curing or for mimicking or re-engineering the intra- and inter-cell physics and dynamics. This can include the use of natural cells, optimised, therapeutic and compound, synthetic ones or combinations of these, as well as cell-free techniques. Where needed, multiscale mathematical modelling and computational simulation can be included. Proposals under this subtopic should also explore the paradigm-changing potential of these technologies, for instance in the bio-medical field.



- b. Bio-electronic medicines and therapies: using adaptive nerve or brain stimulation for precise regulatory control of organs or other biological processes inside the human body, in order to restore or maintain healthy conditions. This includes technologies for bio-electronic medicines, drug-free therapies, adaptive drug release, closed-loop BNCI, more invasive stimulation, or development of neurotransmitter sensor/actuator systems, all within a setting of personalised and adaptive medicine and the tight integration of diagnostic and therapeutic capabilities (theranostics). A Responsible Research and Innovation approach, including aspects of ethics, as well as social science and humanities should be taken into account.

- c. Cognitive neuro-technologies: integrated interdisciplinary approaches combining theory and novel technology-based experiments for understanding the circuits and pathways of higher-level cognitive functions (such as navigation, goal-oriented behaviour, motivation and reward, memory, knowledge and belief formation, reasoning and decision making, emotion, interaction, communication), the related principles of neural coding and operation within and between brain regions and the role of the physical and social/cultural environment in bringing them about. Proposals should focus on non-validated, leading-edge methodologies and technologies specifically relevant to cognitive neuroscience. Target applications could include, for example, adaptive human interfaces, specific brain interfaces and neuro-prosthetics to restore or support cognitive functions or to address unmet therapeutic needs.

Nicolás <b>OJEDA</b>	+34 91 603 77 80	<a href="mailto:nicolas.ojeda@oficinaeuropea.es">nicolas.ojeda@oficinaeuropea.es</a>
Severino <b>FALCÓN</b>	+34 91 603 79 59	<a href="mailto:fet.h2020@mineco.es">fet.h2020@mineco.es</a>
Pablo <b>FERNÁNDEZ</b>	+ 34 934054203	<a href="mailto:pablo.fernandez.gonzalez@upc.edu">pablo.fernandez.gonzalez@upc.edu</a>



- Strategic **investments in key technologies** (e.g. advanced manufacturing, micro-electronics) underpin innovation across existing and emerging sectors.
- Europe needs **to attract more private investment** in research and innovation.
- Europe needs **more innovative SMEs** to create growth and jobs.

## Pilar 2 – Liderazgo Industrial

1) Leadership in enabling & industrial technologies (LEITs) 13.781 Mio. €

1.1 ICT (w/o E-health) 7.939 Mio. €

1.2, 1.3 y 1.5: Nanotech., materials and production 3.797 Mio. €

1.4 Biotechnology 509 Mio. (from FP7-Health)

1.6 Space 1.536 Mio. €

2) Access to Risk Finance 3.538 Mio. €

3) Innovation in SMEs 619 M€

Similar to US SBIR model

## Pilar 3 – Retos Sociales



- Concerns of citizens and society/EU policy objectives (climate, environment, energy, transport etc) cannot be achieved without innovation.
- Breakthrough solutions come from multi-disciplinary collaborations, including social sciences & humanities.
- Promising solutions need to be tested, demonstrated

- Ageing population
- Understanding disease – personalised medicine
- Chronic and infectious disease burden
- Drug development
- Well informed patients put higher demands on healthcare providers
- Request for more personalised health care systems

## 1.1 Understanding health, well-being and disease (4 topics)

- SC1-PM-01-2016: Multi omics for personalised therapies addressing diseases of the immune system
- ▪ SC1-PM-02-2017: New concepts in patient stratification
- ▪ SC1-PM-03-2017: Diagnostic characterisation of rare diseases
- ▪ SC1-PM-04-2016: Networking and optimising the use of population and patient cohorts at EU level

## 1.2. Preventing disease (3 topics)

- SC1-PM-05-2016: The European Human Biomonitoring Initiative
- SC1-PM-06-2016: Vaccine development for malaria and/or neglected infectious diseases
- ▪ SC1-PM-07-2017: Promoting mental health and well-being in the young



## SC1-PM-07-2017: Promoting mental health and well-being in the young

Specific Challenge: Mental well-being<sup>13</sup> is integral to population health and well-being and contributes to the functioning of individuals, families, communities and the social and economic prosperity of society. Mental and behavioural disorders including addictive behaviour place immense burdens on individuals, families and society; they also increase the risk of co-morbidities and social exclusion. Childhood and adolescence are crucial periods for laying the foundations for healthy development and mental well-being. There is compelling evidence that promotion of mental well-being and prevention interventions, when implemented effectively, can reduce risk factors for mental disorders, enhance protective factors for good mental and physical health and lead to lasting positive effects on a range of educational, social and economic outcomes for young people<sup>14</sup>. Medical and psychological factors, family and social factors (including working conditions) as well as digital environments are some of the different determinants impacting the health and well-being of the young. Resilience to adversity will enhance their ability to cope. There is a need for more robust evidence on resilience factors and on effective interventions promoting mental well-being. Developing these in the young offers the possibility of a positive influence on child development in critical/sensitive periods (childhood, adolescence, transition to young adulthood), thanks to early neuroplasticity.

Scope: Proposals should develop population-oriented primary prevention<sup>15</sup> interventions to promote mental well-being of young people and assess them for their effectiveness. The interventions should build on but may go beyond existing state-of-the art knowledge on biological, psychological and social determinants of mental well-being such as societal, cultural, work life, lifestyle, epidemiological, economic and environmental perspectives. The proposals should aim at increasing resilience and mitigating the impact of biological, psychosocial and environmental risk factors. The target group should include young up to 25 years (or a subgroup thereof), which is an age limit often used as many severe disorders start in this period.





The research design should be developed by means of a multidisciplinary approach and involve the young themselves and other relevant stakeholders. Innovative approaches in involving the young and gathering their inputs for the design of the intervention should be considered. The interventions should use a holistic approach, taking gender and health inequality aspects into account, in increasing resilience and empowering the young. The interventions to be developed should reflect the diversity of the different countries and regions in Europe and beyond. The research should pay particular attention to ethical issues. The interventions should be assessed for mental well-being outcomes as well as the economic and social benefits and impact on reducing inequalities. These analyses of impact and effectiveness should be presented in quantitative as well as qualitative terms, in a gender disaggregated way where relevant. The results should be disseminated throughout Europe and beyond in order that the evidence generated is fully exploited.

The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 4 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact: Short or medium term impact, likely during the lifetime of the project:

- Improved mental well-being in the targeted group of young people.
- The innovative interventions will create a strong evidence base for mental well-being promotion programmes in Europe, contributing to greater health equity and improved societal benefits.

Longer term impact, likely beyond the lifetime of the project:

- Improved mental well-being in youth should contribute to reducing school and college/university dropout in the short term, strengthening personal confidence and cognitive function, improving educational efforts and enhancing employability.
- Preventative strategies are established which have a real effect of reducing the occurrence of mental disorders and co-morbidities associated with mental disorders later in life.

Type of Action: Research and Innovation action

*The conditions related to this topic are provided at the end of this call and in the General Annexes.*

# Topics SC1 (2016-2017)

## 1.3 Treating and managing diseases: (4 topics)


- SC1-PM-08–2017: New therapies for rare diseases
- SC1-PM-09–2016: New therapies for chronic diseases
- SC1-PM-10–2017: Comparing the effectiveness of existing healthcare interventions in the adult population
- SC1-PM-11–2016-2017: Clinical research on regenerative medicine

## 1.4 Active ageing and self-management of health: (4 topics)

- SC1-PM-12–2016: PCP - eHealth innovation in empowering the patient
- SC1-PM-13–2016: PPI for deployment and scaling up of ICT solutions for active and healthy ageing
- SC1-PM-14–2016: EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities
- SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age

# Topics SC1 (2016-2017)

## 1.5 Methods and data: (5 topics )

- 
- SC1-PM-16 - 2017: In-silico trials for developing and assessing biomedical products
  - SC1-PM-17 - 2017: Personalised computer models and in-silico systems for well-being
  - SC1-PM-18 - 2016: Big Data supporting Public Health policies
  - SC1-PM-19 - 2017: PPI for uptake of standards for the exchange of digitalised healthcare records
  - SC1-PM-20 - 2017: Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector

## 1.6 Health care provision and integrated care:

- SC1-PM-21 - 2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries

# Topics SC1 (2016-2017)

## Co-ordination activities: (15 topics, 1 ERA Net)

- SC1-HCO-01 - 2016: Valorisation of FP7 Health and H2020 SC1 research results
- SC1-HCO-02 - 2016: Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine
- SC1-HCO-03 - 2017: Implementing the Strategic Research Agenda on Personalised Medicine (**ERA-Net**)
- SC1-HCO-04 - 2016: Towards globalisation of the Joint Programming Initiative on Antimicrobial Resistance
- SC1-HCO-05 - 2016: Coordinating personalised medicine research
- SC1-HCO-06 - 2016: Towards an ERA-NET for building sustainable and resilient health system models
- SC1-HCO-07 - 2017: Global Alliance for Chronic Diseases (GACD)
- SC1-HCO-08 - 2017: Actions to bridge the divide in European health research and innovation
- SC1-HCO-09 - 2016: Support for Europe's leading Health ICT SMEs
- SC1-HCO-10 - 2016: Coordinated Action to support the recognition of Silver Economy opportunities arising from demographic change
- SC1-HCO-11 - 2016: Digital health literacy
- SC1-HCO-12 - 2016: EU-US interoperability roadmap
- SC1-HCO-13 - 2016: EU eHealth Interoperability conformity assessment
- SC1-HCO-14 - 2016: Standardisation needs in the field of ICT for Active and Healthy Ageing

# Topics SC1 (2016-2017)

## Other Actions:

- 1. Subscription fee: Human Frontier Science Programme Organisation
- 2. **InnovFin Infectious Diseases (InnovFin ID) Pilot**
- 3. First interim evaluation of the EDCTP2 programme
- 4. First interim evaluation of the IMI2 programme
- 5. European registry for human embryonic stem cell lines
- 6. Studies, activities of the Scientific Panel for Health, and for conferences, events and outreach activities
- 7. External expertise
- 8. Horizon Price on reducing maternal and new-born morbidity and mortality – the Birth Day Prize
- 9. Grant to the Global Alliance for Chronic Diseases
- 10. Expert group for alternatives to animal testing
- 11. Presidency events – eHealth
- 12. Establishing EU mHealth hub including evidence for the integration of mHealth in the healthcare systems



## Tabla de fechas

Conv.	Nº de topic	Apertura	Fecha cierre
<b>2016</b>	SC1-PM-12 / 13 / 18 SC1-HCO-10 / 11 / 12 / 13 / 14 / 15 / 16	20.10.2015	16.02.2016
	SC1-PM-14		12.04.2016
	SC1-PM-01 / 04 / 05 / 06 / 09 / 11 / 21		13.04.2016
<b>2017</b>	SC1-PM-02 / 07/ 08 /10	29.07.2016	<b>1st stage</b> 04.10.2016
			<b>2nd stage</b> 11.04.2017
	SC1-PM-03 / 20 SC1-HCO-03 / 07 / 08		11.04.2017
	SC1-PM-15	20.09.2016	31.01.2017
	SC1-PM-16 / 17 / 19	08.11.2016	14.03.2017



- Approx. € 400 M. (2016) y € 350 M. (2017) (línea presupuestaria de DG-RTD)
- Approx. € 100 M. (2016) y € 87 M. (2017) (línea presupuestaria DG-CNECT)
- Menor número de acciones con respecto a SC1 WP 2014-2015

# Tasas de financiación

100% costes directos, 25% costes indirectos, excepto:

- SC1-PM-13–2016, SC1-PM-19–2017
  - The funding rate for PPI actions is **limited to 35% of the total eligible costs** to leverage co-financing from the procurers in this specific case.
  
- SC1-PM-12–2016
  - The funding rate for PCP actions is **limited to 90% of the total eligible costs** to leverage co-financing from the procurers in this specific case.

# Work Programme 2016 – 2017: SC6

## Europe in a changing world- inclusive, innovative and reflective societies

### Prizes



### Horizon Prize for Social Innovation in Europe

Specific challenge to be addressed (2 Million)

EC (in cooperation with the European Investment Bank Institute) has invited citizens to "vote" through an easy to use on-line system, among 5 different objectives:

- *Obesity in children*
- ***Aging population***
- *Immigrants*
- *Women*
- *Clean energy*

**Launch of the contest : 1st quarter of 2016**

# SC7 Secure societies – Protecting freedom and security of Europe and its citizens

## ■ Call - Digital Security Focus Area

- **DS-03-2016:** Increasing digital security of health related data on a systemic level



**RIA single-stage** evaluation  
deadline:16 Feb 2016

## SC6. Europe in a changing world- inclusive, innovative and reflective societies

### Prizes

#### Horizon Prize for Social Innovation in Europe

- Specific challenge to be addressed (2 Million)
- EC (in cooperation with the European Investment Bank Institute) has invited citizens to "vote" through an easy to use on-line system, among 5 different objectives:

- *Obesity in children*
- ***Aging population***
- *Immigrants*
- *Women*
- *Clean energy*




- **Launch of the contest : 1st quarter of 2016**

# El Instrumento PYME

## SME Instrument

### SME instrument: 3 phases



HORIZON 2020



## SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector

- a) Cell technologies in medical applications (all phase 1 and phase 2 deadlines in 2016 and 2017)
- b) Clinical research for the validation of biomarkers and/or diagnostic medical devices (**¡solo fase 2!**)

## SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well (Fases 1, 2 y 3)

# Características del SME Instrument

- 100% de financiación SMEInst-05-2016-2017;
- 70% en SMEInst-06-2016-2017
- Menos bottom-up en SC1 vs otros retos
- Convocatoria abierta con fechas de corte
- Evaluación:
  - Fase 1: Phase 1 thresholds:
    - Excellence: 4/5 ; Impact: 4/5 ; Implementation: 4/5
    - Minimum overall threshold: 13/15
    - Score = Excellence + Impact \*1,5 + Implementation
  - Fase 2: Phase 2 thresholds :
    - Excellence: 3/5 ; Impact: 4/5 ; Implementation: 3/5
    - Minimum overall threshold: 12/15
    - Score = Excellence + Impact \*1,5 + Implementation



# Calendario de fechas de corte para el SME Instrument

2016		2017	
Fase I	Fase II	Fase I	Fase II
24 feb.	3 feb.	15 feb.	18 enero
3 mayo	14 abril	3 mayo	6 abril
7 sept.	15 junio	6 sept.	1 junio
9 nov.	13 oct.	8 nov.	18 oct.

# Fast Track to Innovation

## Condiciones de la convocatoria

- For 2015 and 2016: 200 Mio € (100 + 100)
- About 50-70 actions (projects) will be funded / year
- Grants for up to 3 Mio € possible (maximum!)
- -> approximately 20 actions per Cut-off to be funded for all themes (bottom-up!)

**Highest competition and very high oversubscription to be expected!**

Cut-off dates 2015	29/4/2015	1/9/2015	1/12/2015
Cut-off-dates 2016	TBD	TBD	TBD

- Advanced and specific research and development
- Advanced performance testing
- Piloting
- Demonstration activities
- Final validation of a system in the operational environment
- Business model validation
- Marketing activities (not purely commercial)
- Activities for strategic commercial and technical relevance

## **Level of development:**

- Technology readiness level (TRL)
- TRL 6 -> TRL 9 in very short time frame
- TRL 6 is minimum requirement (i.e. demonstration in a relevant environment)

# Otras Acciones: InnovFin Infectious Diseases (InnovFin ID) Piloto

<http://www.eib.org/innovfin>


Un nuevo instrumento financiero en R&D:

- Desarrollado conjuntamente por la Comisión Europea y el Banco Europeo de Inversiones
- Presentado el 15 Junio 2015 en Riga durante la 'Primera Semana de la Empresa Innovadora'
- Creado como InnovFin – Fondos para innovadores
- Concede préstamos entre €7,5 y €75 millones a actores innovadores en el desarrollo de vacunas, medicamentos, dispositivos médicos y de diagnóstico, e infraestructuras de investigación para combatir las enfermedades infecciosas

**InnovFin**  
EU Finance for Innovators



European  
Investment  
Bank



EUROPEAN  
INVESTMENT  
FUND



# Pilar 1

- **ERC-IDEAS: 13.268 M€** (presupuesto duplicado frente a PM7)
  - Más enfocado jóvenes investigadores e investigación básica, pero
  - Sin olvidar la visión sobre el impacto de la investigación!
- **FET (Tecnologías Futuras y Emergentes): 3.100 M€**
  - Las TIC como herramientas para alcanzar objetivos
- **Marie Sklodowska Curie (Movilidad): 5.752 M€**
- **Infraestructuras (ESFRI): 2.478 M€ (x2 en comparación con PM7)**
  - Instrumento para avanzar en el Espacio Europeo de Investigación (ERA)
  - Promover el acceso a infraestructuras europeas de I+D+i

# Posibles topics relacionados con biomedicina en el Pilar 2 (Liderazgo industrial)

## **ADVANCED MATERIALS AND NANOTECHNOLOGIES FOR HEALTHCARE .... 42**

NMBP-09-2016: Biomaterials for diagnosis and treatment of demyelination disorders of the Central Nervous System.....	42
NMBP-10-2016: Nanoformulation of biologicals .....	44
NMBP-11-2016: ERA-NET on Nanomedicine .....	46
NMBP-12-2017: Development of a reliable methodology for better risk management of engineered biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices .....	47
NMBP-13-2017: Cross-cutting KETs for diagnostics at the point-of-care.....	48
NMBP-14-2017: Regulatory Science Framework for assessment of risk benefit ratio of Nanomedicines and Biomaterials.....	50
NMBP-15-2017: Nanotechnologies for imaging cellular transplants and regenerative processes in vivo .....	52
NMBP-16-2017: Mobilising the European nano-biomedical ecosystem .....	53

# Contenido

- Financiación de la I+D+i en Salud Mental y Neurociencias en H2020
  - Oportunidades en Pilares 1, 2 y 3
- Oportunidades en la Iniciativa de Medicamentos Innovadores (IMI2)
- Oportunidades en ERA-Nets y JPIs


## La Iniciativa de Medicamentos Innovadores 2






Cierre 12 de enero 2015

## Call topics

- 
- Development of **Quantitative System Toxicology** (QST) approaches to improve the understanding of the **safety** of new medicines
  - Establishing impact of **RSV (respiratory syncytial virus)** infection, resultant disease and public health approach to reducing the consequences



Topics under the **Big Data for Better Outcomes** programme:

- 
- Real World Outcomes Across the **AD (Alzheimer's disease)** Spectrum (ROADS) to Better Care
  - Development of an outcomes-focused platform to empower policy makers and clinicians to optimise care for patients with **haematologic malignancies**

<http://www.imi.europa.eu/content/stage-1-17>

# Hacia la 7ª convocatoria de IMI2

<http://www.imi.europa.eu/content/future-topics>

- 
- 
1. Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks
  2. Validation of translational imaging methods in drug safety assessment (TRISTAN)
  3. Identification of drugable targets modulating misfolded proteins in major neurodegenerative diseases
  4. Pathological neuron-glia interactions in neuropathic pain
  5. Dry age-related macular degeneration: development of novel clinical endpoints for clinical trials with a regulatory and patient access intention
  6. A comprehensive 'paediatric preclinical POC platform' to enable clinical molecule development for children with cancer
  7. Identification and validation of non-invasive markers across the spectrum of nonalcoholic fatty liver disease (NAFLD)

## Topics under the Big Data for Better Outcomes programme

1. Coordination and support action (CSA) for the big data for better outcomes programme
2. Increase access and use of high quality data to improve clinical outcomes in heart failure (HF), atrial fibrillation (AF), and acute coronary syndrome (ACS) patients

- Financiación de la I+D+i en Salud Mental y Neurociencias en H2020
  - Oportunidades en Pilares 1, 2 y 3
- Oportunidades en la Iniciativa de Medicamentos Innovadores (IMI2)
- Oportunidades en ERA-Nets y JPIs

# ERA-Nets, JPIs, art. 185

## ERA-Nets:

- E-RARE-2
- TRANSCAN
- EuroNanoMed
- ERA-Net Lac
- Neuron
- Infect-ERA
- ERASysApp
- ERA-CVD

## Art. 185:

- AAL2
- EDCTP2



## • JPIs:

- Enfermedades Neurodegenerativas
- Resistencia Antimicrobiana
- Dieta saludable
- Cambio demográfico

## E-RARE 3

- Próxima convocatoria 2016
- Financiación ISCIII: 500.000 €
- Beneficiarios:

	Coordinador	Socio
Hospitales y centros del SNS	SI	SI
Institutos de Investigación Sanitaria acreditados (IIS)	SI	NO
CIBER or CIBERNED	SI	NO

- Topic: Estudios clínicos sobre nuevos usos terapéuticos de moléculas ya existentes
- Excluido cánceres raros, infecciosas raras
- Preanuncio el **6 de noviembre**

Contacto: Eduard Güell [eguell@isciit.es](mailto:eguell@isciit.es)

- Topics 2016 (ETPN): Diagnosticos, Dianas terapéuticas y Medicina Regenerativa
- Una fase de envío de propuestas
- Abre el 26 de noviembre
- Compromiso **ISCIII: 0,25 M €**. Beneficiarios: Hospitales y centros del SNS (CIBER e IIS si coordinadores del consorcio)
- Compromiso **MINECO: 0,5 M €**. Beneficiarios: centros de I+D sin ánimo de lucro (universidades, OPIS, CSIC...)



Contacto: [doricampo@isciii.es](mailto:doricampo@isciii.es)

- 2 socios españoles: ISCIII y MINECO

## **Convocatoria 2015:**

- Proyectos en evaluación. Contribución MINECO: 0,8 M€
- ELSA – Aspectos éticos, sociales y legales. Financiación ISCIII: 50.000 €

- 2 socios españoles: ISCIII y MINECO

## **Convocatoria 2015:**

- Proyectos en evaluación. Contribución MINECO: 0,8 M€
- ELSA – Aspectos éticos, sociales y legales. Financiación ISCIII: 50.000 €

## Acciones futuras:

- Enero 2016 Era-net Cofund (NEURON 3)
- Pre-anuncio: diciembre 2015
  - Lanzamiento de la convocatoria cofinanciada a principios de 2016
  - Topic: “Brain disorders and injuries caused by external insults, such as brain and spinal cord trauma, infections, and toxic influence”
  - Contribución ISCIII: 500.000 €
  - Contribución MINECO: 1.000.000 €

Contacto: Irene Sánchez García [isanchezgarcia@isciii.es](mailto:isanchezgarcia@isciii.es)  
Tel.: 918222488



- **Neurodegenerative Diseases/Alzheimer's - JPND**
  - <http://www.neurodegenerationresearch.eu/>
- Agriculture, food security and climate change
- **A healthy diet for a healthy life – HDHL**
  - <http://www.healthydietforhealthylife.eu/>
- Cultural heritage & global change
- Urban Europe
- Climate Knowledge
- **More Years, Better Lives – MYBL**
  - <http://www.jp-demographic.eu/>
- **Antimicrobial Resistance – AMR**
  - <http://www.jpamr.eu/>
- Water Challenges
- Healthy & Productive Seas and Oceans

# JPND – Joint Programming in Neurodegenerative Disease

## **2015:**

"A call for European research projects on neurodegenerative diseases: risk and protective factors, longitudinal cohort approaches and advanced experimental models" (co-funded call with European Commission)

## **2014:**

"A Call for Proposals for Working Groups to Inform Cohort Studies in Neurodegenerative Disease Research"

## **2013:**

"A call for European research projects for cross-disease analysis of pathways related to neurodegenerative diseases"

"A call for European research projects for pilot studies for preventive strategies related to neurodegenerative diseases"

## **2012:**

"A call for European research projects for the identification of genetic, epigenetic and environmental risk and protective factors"

"A call for European research projects for the evaluation of health care policies, strategies and interventions"

## **2011:**

Pilot JPND Joint Transnational Call for optimisation of biomarkers and harmonisation of their use

**Juan E. Riese**

[jriese@eu-isciii.es](mailto:jriese@eu-isciii.es)

